- EMPACT-MI: A streamlined, multicenter, randomized, parallel group, double-blind placebo-controlled superiority trial to evaluate the effect of EMPAgliflozin on hospitalization for heart failure and mortality in patients with acute Myocardial Infarction
- Patient population: high-risk patients hospitalized for acute myocardial infarction
- Main eligibility criteria:
- Acute myocardial infarction (type 1 - i.e, not secondary to other acute medical condition)
- Heart failure symptoms and need for therapy
- No history of heart failure
- Intervention: empagliflozin 10mg daily vs placebo
- FINEARTS-HF: Finerenone study to investigate effectiveness and safety compared to placebo in patients with heart failure. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥ 40% (LVEF ≥ 40%)
- Patient population: heart failure with mildly reduced or preserved left ventricular ejection fraction (LVEF)
- Main eligibility criteria:
- Chronic heart failure (NYHA II-IV) and LVEF ≥40%
- No spironolactone use
- On diuretics
- Intervention: finerenone vs placebo
- PROACTIVE-HF: A Prospective, Multi-Center, Randomized, Controlled, Single Blind Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in New York Heart Association (NYHA) Class III Heart Failure Patients.
- Patient population: patients with heart failure
- Main eligibility criteria:
- Heart failure diagnosis
- On diuretics
- No myocardial infarction or stroke in the past 3 months
- Intervention: Cordella™ Pulmonary Artery Sensor System
- PARAGLIDE-HF: A multicenter, randomized, double-blind, double-dummy, parallel group, active controlled study to evaluate the effect of sacubitril/valsartan (LCZ696) versus valsartan on changes in NT-proBNP and outcomes, safety, and tolerability in HFpEF patients with acute decompensated heart failure (ADHF) who have been stabilized during hospitalization and initiated in-hospital or within 30 days post-discharge
- Patient population: patients hospitalized for acute heart failure and preserved left ventricular ejection fraction (LVEF)
- Main eligibility criteria:
- Acute heart failure diagnosis
- In hospital or recently hospitalized for heart failure
- Mildly reduced or preserved LVEF (>40%)
- Intervention: sacubitril-valsartan vs valsartan
- V-INITIATE: A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy to usual care on LDL cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease and elevated LDL-C (≥70 mg/dL) despite receiving maximally tolerated statin therapy (VICTORION INITIATE).
- Patient population: high cardiovascular risk patients
- Main eligibility criteria:
- Prior myocardial infarction
- History of cardiovascular disease
- Prior peripheral arterial disease
- Intervention: inclisiran vs standard of care
- SUMMIT: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT)
- Patient population: patients with heart failure and preserved ejection fraction and obesity
- Main eligibility criteria:
- Heart failure (NYHA class II-IV) and left ventricular ejection fraction (LVEF) ≥50%
- Stable on medications for heart failure for 4 weeks
- Body mass index (BMI) ≥30
- Intervention: tirzepatide vs. placebo